Melbourne, Australia 18 March 2026 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.
Details of the poster presentations are as follows:
|
Presentation Title |
Phase Ib clinical evaluation of a novel CD55- and FcRn-bioselected RNA oncolytic virus, IVX037, combined with sintilimab (anti-PD-1) in advanced microsatellite-stable colorectal cancer |
High-Affinity Receptor Bio-Selected Novel Oncolytic RNA Virus, IVX055, Demonstrates Potent Anti-Tumour Activity in Human NSCLC, Hepatocellular Carcinoma, and Bladder Cancer with Potential for Immunotherapeutic Combinations |
|
Presentation Date and Time |
Tuesday, April 21, 2026, 9am- 12noon Pacific time |
Tuesday, April 21, 2026, 9am- 12noon Pacific time |
|
Abstract Number |
CT183 |
4377 |
|
Location |
Poster Section 50 |
Poster Section 10 |
|
Session Title |
Phase I Clinical Trials |
Vaccine Platforms and Target Identification |
About the AACR Annual Meeting 2026
The AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California, is one of the world’s largest and most influential conferences dedicated to cancer research. Organized by the American Association for Cancer Research (AACR), the meeting brings together more than 20,000 scientists, clinicians, healthcare professionals, patient advocates, and industry leaders from around the globe to share the latest advances in cancer biology, translational science, and clinical oncology. The annual meeting serves as a premier forum for the presentation of cutting-edge discoveries and emerging therapeutic approaches aimed at improving outcomes for patients with cancer.
About ImmVirX
ImmVirX is developing targeted oncolytic immunotherapies for cancer patients with advanced/metastatic disease and limited treatment options. Our lead asset, IVX037, is currently in clinical studies, and our second candidate, IVX055, is expected to enter the clinic in late 2026.
Our novel therapies harness the power of viruses to preferentially infect and destroy cancer cells while stimulating the immune system to generate both innate and adaptive anti-tumor responses. By combining direct oncolytic activity with immune activation, our approach is designed to enhance the body’s ability to recognize and eliminate cancer.
Our proprietary bio-selection platform enables the development of RNA viruses that target receptor proteins highly expressed on specific cancer cell types. Through this targeted approach, our oncolytic virotherapies seek to improve the effectiveness of immunotherapy in cancers with high unmet need, including colorectal, gastric, ovarian, liver, and lung cancers.
Website: https://www.immvirx.com/
LinkedIn: https://www.linkedin.com/company/immvirx
X: https://x.com/immvirx
Media Contact
Dr. Malcolm McColl
Chief Executive Officer, Acting Chairman and Co-Founder
E: [email protected]
